Structural and functional insights into the juxtamembranous amino-terminal tail and extracellular loop regions of class B GPCRs

British Journal of Pharmacology

Volumn 171, Issue 5, 2014, Pages 1085-1101

  Dong, M ^a   Koole, C ^b   Wootten, D ^b   Sexton, P M ^b   Miller, L J ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b MONASH UNIVERSITY   (Australia)

Author keywords

class B GPCR; ligand binding; structure activity series

Indexed keywords

CHIMERIC PROTEIN; CORTICOTROPIN RELEASING FACTOR; CYSTEINE; G PROTEIN COUPLED RECEPTOR; LIGAND; SECRETIN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; CYSTEINE TRAPPING; EXTRACELLULAR LOOP REGION; INTRACELLULAR SIGNALING; JUXTAMEMBRANOUS AMINO TERMINAL TAIL; MOLECULAR DOCKING; MUTAGENESIS; NUCLEOTIDE SEQUENCE; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN MOTIF; PROTEIN STRUCTURE; REVIEW; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION;

CLASS B GPCR; LIGAND BINDING; STRUCTURE-ACTIVITY SERIES;

AMINO ACID SEQUENCE; HUMANS; LIGANDS; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84895141079     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12293     Document Type: Review

References (123)

1. Adams AE, Bisello A, Chorev M, Rosenblatt M, Suva LJ, (1998). Arginine 186 in the extracellular N-terminal region of the human parathyroid hormone 1 receptor is essential for contact with position 13 of the hormone. Mol Endocrinol 12: 1673-1683.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
3. Al-Sabah S, Donnelly D, (2003). The positive charge at Lys-288 of the glucagon-like peptide-1 (GLP-1) receptor is important for binding the N-terminus of peptide agonists. FEBS Lett 553: 342-346.
4. Assil-Kishawi I, Abou-Samra AB, (2002). Sauvagine cross-links to the second extracellular loop of the corticotropin-releasing factor type 1 receptor. J Biol Chem 277: 32558-32561.
5. Barwell J, Conner A, Poyner DR, (2011). Extracellular loops 1 and 3 and their associated transmembrane regions of the calcitonin receptor-like receptor are needed for CGRP receptor function. Biochim Biophys Acta 1813: 1906-1916.
6. Barwell J, Woolley MJ, Wheatley M, Conner AC, Poyner DR, (2012). The role of the extracellular loops of the CGRP receptor, a family B GPCR. Biochem Soc Trans 40: 433-437.
7. Behar V, Bisello A, Rosenblatt M, Chorev M, (1999). Direct identification of two contact sites for parathyroid hormone (PTH) in the novel PTH-2 receptor using photoaffinity cross-linking. Endocrinology 140: 4251-4261.
8. Behar V, Bisello A, Bitan G, Rosenblatt M, Chorev M, (2000). Photoaffinity cross-linking identifies differences in the interactions of an agonist and an antagonist with the parathyroid hormone/parathyroid hormone-related protein receptor. J Biol Chem 275: 9-17.
9. Bergwitz C, Jusseaume SA, Luck MD, Juppner H, Gardella TJ, (1997). Residues in the membrane-spanning and extracellular loop regions of the parathyroid hormone (PTH)-2 receptor determine signaling selectivity for PTH and PTH-related peptide. J Biol Chem 272: 28861-28868.
10. Bisello A, Adams AE, Mierke DF, Pellegrini M, Rosenblatt M, Suva LJ, et al. (1998). Parathyroid hormone-receptor interactions identified directly by photocross-linking and molecular modeling studies. J Biol Chem 273: 22498-22505.
11. Buggy JJ, Livingston JN, Rabin DU, Yoo-Warren H, (1995). Glucagon.glucagon-like peptide I receptor chimeras reveal domains that determine specificity of glucagon binding. J Biol Chem 270: 7474-7478.
12. Carter PH, Shimizu M, Luck MD, Gardella TJ, (1999). The hydrophobic residues phenylalanine 184 and leucine 187 in the type-1 parathyroid hormone (PTH) receptor functionally interact with the amino-terminal portion of PTH-(1-34). J Biol Chem 274: 31955-31960.
13. Ceraudo E, Murail S, Tan YV, Lacapere JJ, Neumann JM, Couvineau A, et al. (2008). The vasoactive intestinal peptide (VIP) alpha-Helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/Pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics. Mol Endocrinol 22: 147-155.
14. Ceraudo E, Hierso R, Tan YV, Murail S, Rouyer-Fessard C, Nicole P, et al. (2012). Spatial proximity between the VPAC1 receptor and the amino terminus of agonist and antagonist peptides reveals distinct sites of interaction. FASEB J 26: 2060-2071.
15. Chen Q, Pinon DI, Miller LJ, Dong M, (2009). Molecular basis of glucagon-like peptide 1 docking to its intact receptor studied with carboxyl-terminal photolabile probes. J Biol Chem 284: 34135-34144.
16. Chen Q, Pinon DI, Miller LJ, Dong M, (2010). Spatial approximations between residues 6 and 12 in the amino-terminal region of glucagon-like peptide 1 and its receptor: a region critical for biological activity. J Biol Chem 285: 24508-24518.
17. Conner AC, Hay DL, Simms J, Howitt SG, Schindler M, Smith DM, et al. (2005). A key role for transmembrane prolines in calcitonin receptor-like receptor agonist binding and signalling: implications for family B G-protein-coupled receptors. Mol Pharmacol 67: 20-31.
18. Conner AC, Simms J, Barwell J, Wheatley M, Poyner DR, (2007). Ligand binding and activation of the CGRP receptor. Biochem Soc Trans 35: 729-732.
19. Couvineau A, Rouyer-Fessard C, Maoret JJ, Gaudin P, Nicole P, Laburthe M, (1996). Vasoactive intestinal peptide (VIP)1 receptor. Three nonadjacent amino acids are responsible for species selectivity with respect to recognition of peptide histidine isoleucineamide. J Biol Chem 271: 12795-12800.
20. Dautzenberg FM, Higelin J, Brauns O, Butscha B, Hauger RL, (2002). Five amino acids of the Xenopus laevis CRF (corticotropin-releasing factor) type 2 receptor mediate differential binding of CRF ligands in comparison with its human counterpart. Mol Pharmacol 61: 1132-1139.
21. DeAlmeida VI, Mayo KE, (1998). Identification of binding domains of the growth hormone-releasing hormone receptor by analysis of mutant and chimeric receptor proteins. Mol Endocrinol 12: 750-765.
22. Di Paolo E, De Neef P, Moguilevsky N, Petry H, Bollen A, Waelbroeck M, et al. (1998). Contribution of the second transmembrane helix of the secretin receptor to the positioning of secretin. FEBS Lett 424: 207-210.
23. Di Paolo E, Petry H, Moguilevsky N, Bollen A, De Neef P, Waelbroeck M, et al. (1999a). Mutations of aromatic residues in the first transmembrane helix impair signalling by the secretin receptor. Receptors Channels 6: 309-315.
24. Di Paolo E, Vilardaga JP, Petry H, Moguilevsky N, Bollen A, Robberecht P, et al. (1999b). Role of charged amino acids conserved in the vasoactive intestinal polypeptide/secretin family of receptors on the secretin receptor functionality. Peptides 20: 1187-1193.
25. Dickson L, Finlayson K, (2009). VPAC and PAC receptors: from ligands to function. Pharmacol Ther 121: 294-316.
26. Dong M, Miller LJ, (2002). Molecular pharmacology of the secretin receptor. Receptors Channels 8: 189-200.
27. Dong M, Wang Y, Hadac EM, Pinon DI, Holicky E, Miller LJ, (1999a). Identification of an interaction between residue 6 of the natural peptide ligand and a distinct residue within the amino-terminal tail of the secretin receptor. J Biol Chem 274: 19161-19167.
28. Dong M, Wang Y, Pinon DI, Hadac EM, Miller LJ, (1999b). Demonstration of a direct interaction between residue 22 in the carboxyl-terminal half of secretin and the amino-terminal tail of the secretin receptor using photoaffinity labeling. J Biol Chem 274: 903-909.
29. Dong M, Asmann YW, Zang M, Pinon DI, Miller LJ, (2000). Identification of two pairs of spatially approximated residues within the carboxyl terminus of secretin and its receptor. J Biol Chem 275: 26032-26039.
30. Dong M, Zang M, Pinon DI, Li Z, Lybrand TP, Miller LJ, (2002). Interaction among four residues distributed through the secretin pharmacophore and a focused region of the secretin receptor amino terminus. Mol Endocrinol 16: 2490-2501.
31. Dong M, Li Z, Zang M, Pinon DI, Lybrand TP, Miller LJ, (2003). Spatial approximation between two residues in the mid-region of secretin and the amino terminus of its receptor. Incorporation of seven sets of such constraints into a three-dimensional model of the agonist-bound secretin receptor. J Biol Chem 278: 48300-48312.
32. Dong M, Li Z, Pinon DI, Lybrand TP, Miller LJ, (2004a). Spatial approximation between the amino terminus of a peptide agonist and the top of the sixth transmembrane segment of the secretin receptor. J Biol Chem 279: 2894-2903.
33. Dong M, Pinon DI, Cox RF, Miller LJ, (2004b). Importance of the amino terminus in secretin Family G protein-coupled receptors: intrinsic photoaffinity labeling establishes initial docking constraints for the calcitonin receptor. J Biol Chem 279: 1167-1175.
34. Dong M, Pinon DI, Cox RF, Miller LJ, (2004c). Molecular approximation between a residue in the amino-terminal region of calcitonin and the third extracellular loop of the class B G protein-coupled calcitonin receptor. J Biol Chem 279: 31177-31182.
35. Dong M, Pinon DI, Miller LJ, (2005). Insights into the structure and molecular basis of ligand docking to the G protein-coupled secretin receptor using charge-modified amino-terminal agonist probes. Mol Endocrinol 19: 1821-1836.
36. Dong M, Pinon DI, Asmann YW, Miller LJ, (2006). Possible endogenous agonist mechanism for the activation of secretin family G protein-coupled receptors. Mol Pharmacol 70: 206-213.
37. Dong M, Lam PC, Gao F, Hosohata K, Pinon DI, Sexton PM, et al. (2007). Molecular approximations between residues 21 and 23 of secretin and its receptor: development of a model for peptide docking with the amino terminus of the secretin receptor. Mol Pharmacol 72: 280-290.
38. Dong M, Gao F, Pinon DI, Miller LJ, (2008a). Insights into the structural basis of endogenous agonist activation of family B G protein-coupled receptors. Mol Endocrinol 22: 1489-1499.
39. Dong M, Lam PC, Pinon DI, Sexton PM, Abagyan R, Miller LJ, (2008b). Spatial approximation between secretin residue five and the third extracellular loop of its receptor provides new insight into the molecular basis of natural agonist binding. Mol Pharmacol 74: 413-422.
40. Dong M, Cox RF, Miller LJ, (2009). Juxtamembranous region of the amino terminus of the family B G protein-coupled calcitonin receptor plays a critical role in small-molecule agonist action. J Biol Chem 284: 21839-21847.
41. Dong M, Lam PC, Pinon DI, Orry A, Sexton PM, Abagyan R, et al. (2010). Secretin occupies a single protomer of the homodimeric secretin receptor complex: insights from photoaffinity labeling studies using dual sites of covalent attachment. J Biol Chem 285: 9919-9931.
42. Dong M, Lam PC, Pinon DI, Hosohata K, Orry A, Sexton PM, et al. (2011). Molecular basis of secretin docking to its intact receptor using multiple photolabile probes distributed throughout the pharmacophore. J Biol Chem 286: 23888-23899.
43. Dong M, Pinon DI, Miller LJ, (2012a). Site of action of a pentapeptide agonist at the glucagon-like peptide-1 receptor. Insight into a small molecule agonist-binding pocket. Bioorg Med Chem Lett 22: 638-641.
44. Dong M, Xu X, Ball AM, Makhoul JA, Lam PC, Pinon DI, et al. (2012b). Mapping spatial approximations between the amino terminus of secretin and each of the extracellular loops of its receptor using cysteine trapping. FASEB J 26: 5092-5105.
45. Donnelly D, (1997). The arrangement of the transmembrane helices in the secretin receptor family of G-protein-coupled receptors. FEBS Lett 409: 431-436.
46. Du K, Nicole P, Couvineau A, Laburthe M, (1997). Aspartate 196 in the first extracellular loop of the human VIP1 receptor is essential for VIP binding and VIP-stimulated cAMP production. Biochem Biophys Res Commun 230: 289-292.
47. Foord SM, Bonner TI, Neubig RR, Rosser EM, Pin JP, Davenport AP, et al. (2005). International Union of Pharmacology. XLVI. G protein-coupled receptor list. Pharmacol Rev 57: 279-288.
48. Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB, (2003). The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 63: 1256-1272.
49. Frimurer TM, Bywater RP, (1999). Structure of the integral membrane domain of the GLP1 receptor. Proteins 35: 375-386.
50. Gardella TJ, Juppner H, Wilson AK, Keutmann HT, Abou-Samra AB, Segre GV, et al. (1994). Determinants of [Arg2]PTH-(1-34) binding and signaling in the transmembrane region of the parathyroid hormone receptor. Endocrinology 135: 1186-1194.
51. Gardella TJ, Luck MD, Fan MH, Lee C, (1996). Transmembrane residues of the parathyroid hormone (PTH)/PTH-related peptide receptor that specifically affect binding and signaling by agonist ligands. J Biol Chem 271: 12820-12825.
52. Gaudin P, Couvineau A, Maoret JJ, Rouyer-Fessard C, Laburthe M, (1995). Mutational analysis of cysteine residues within the extracellular domains of the human vasoactive intestinal peptide (VIP) 1 receptor identifies seven mutants that are defective in VIP binding. Biochem Biophys Res Commun 211: 901-908.
53. Gaylinn BD, (2002). Growth hormone releasing hormone receptor. Receptors Channels 8: 155-162.
54. Gelling RW, Wheeler MB, Xue J, Gyomorey S, Nian C, Pederson RA, et al. (1997). Localization of the domains involved in ligand binding and activation of the glucose-dependent insulinotropic polypeptide receptor. Endocrinology 138: 2640-2643.
55. Gensure RC, Gardella TJ, Juppner H, (2001). Multiple sites of contact between the carboxyl-terminal binding domain of PTHrP-(1-36) analogs and the amino-terminal extracellular domain of the PTH/PTHrP receptor identified by photoaffinity cross-linking. J Biol Chem 276: 28650-28658.
56. Gensure RC, Shimizu N, Tsang J, Gardella TJ, (2003). Identification of a contact site for residue 19 of parathyroid hormone (PTH) and PTH-related protein analogs in transmembrane domain two of the type 1 PTH receptor. Mol Endocrinol 17: 2647-2658.
57. Gkountelias K, Tselios T, Venihaki M, Deraos G, Lazaridis I, Rassouli O, et al. (2009). Alanine scanning mutagenesis of the second extracellular loop of type 1 corticotropin-releasing factor receptor revealed residues critical for peptide binding. Mol Pharmacol 75: 793-800.
58. Granier S, Kobilka B, (2012). A new era of GPCR structural and chemical biology. Nat Chem Biol 8: 670-673.
59. Granier S, Manglik A, Kruse AC, Kobilka TS, Thian FS, Weis WI, et al. (2012). Structure of the delta-opioid receptor bound to naltrindole. Nature 485: 400-404.
60. Greenberg Z, Bisello A, Mierke DF, Rosenblatt M, Chorev M, (2000). Mapping the bimolecular interface of the parathyroid hormone (PTH)-PTH1 receptor complex: spatial proximity between Lys(27) (of the hormone principal binding domain) and leu(261) (of the first extracellular loop) of the human PTH1 receptor. Biochemistry 39: 8142-8152.
61. ter Haar E, Koth CM, Abdul-Manan N, Swenson L, Coll JT, Lippke JA, et al. (2010). Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism. Structure 18: 1083-1093.
62. Hoare SR, (2005). Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. Drug Discov Today 10: 417-427.
63. Holtmann MH, Ganguli S, Hadac EM, Dolu V, Miller LJ, (1996). Multiple extracellular loop domains contribute critical determinants for agonist binding and activation of the secretin receptor. J Biol Chem 271: 14944-14949.
64. Ji TH, Grossmann M, Ji I, (1998). G protein-coupled receptors. I. Diversity of receptor-ligand interactions. J Biol Chem 273: 17299-17302.
65. Knudsen SM, Tams JW, Wulff BS, Fahrenkrug J, (1997). A disulfide bond between conserved cysteines in the extracellular loops of the human VIP receptor is required for binding and activation. FEBS Lett 412: 141-143.
66. Koole C, Wootten D, Simms J, Miller LJ, Christopoulos A, Sexton PM, (2012a). Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation. J Biol Chem 287: 3642-3658.
67. Koole C, Wootten D, Simms J, Savage EE, Miller LJ, Christopoulos A, et al. (2012b). Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) differentially regulates orthosteric but not allosteric agonist binding and function. J Biol Chem 287: 3659-3673.
68. Koole C, Pabreja K, Savage EE, Wootten D, Furness SG, Miller LJ, et al. (2013). Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function. Biochem Soc Trans 41: 172-179.
69. Koth CM, Abdul-Manan N, Lepre CA, Connolly PJ, Yoo S, Mohanty AK, et al. (2010). Refolding and characterization of a soluble ectodomain complex of the calcitonin gene-related peptide receptor. Biochemistry 49: 1862-1872.
70. Koth CM, Murray JM, Mukund S, Madjidi A, Minn A, Clarke HJ, et al. (2012). Molecular basis for negative regulation of the glucagon receptor. Proc Natl Acad Sci U S A 109: 14393-14398.
71. Kraetke O, Holeran B, Berger H, Escher E, Bienert M, Beyermann M, (2005). Photoaffinity cross-linking of the corticotropin-releasing factor receptor type 1 with photoreactive urocortin analogues. Biochemistry 44: 15569-15577.
72. Kuwasako K, Hay DL, Nagata S, Hikosaka T, Kitamura K, Kato J, (2012). The third extracellular loop of the human calcitonin receptor-like receptor is crucial for the activation of adrenomedullin signalling. Br J Pharmacol 166: 137-150.
73. Lee C, Gardella TJ, Abou-Samra AB, Nussbaum SR, Segre GV, Potts JT, Jr, et al. (1994). Role of the extracellular regions of the parathyroid hormone (PTH)/PTH-related peptide receptor in hormone binding. Endocrinology 135: 1488-1495.
74. Lee C, Luck MD, Juppner H, Potts JT, Jr, Kronenberg HM, Gardella TJ, (1995). Homolog-scanning mutagenesis of the parathyroid hormone (PTH) receptor reveals PTH-(1-34) binding determinants in the third extracellular loop. Mol Endocrinol 9: 1269-1278.
75. Liaw CW, Grigoriadis DE, Lorang MT, De Souza EB, Maki RA, (1997a). Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. Mol Endocrinol 11: 2048-2053.
76. Liaw CW, Grigoriadis DE, Lovenberg TW, De Souza EB, Maki RA, (1997b). Localization of ligand-binding domains of human corticotropin-releasing factor receptor: a chimeric receptor approach. Mol Endocrinol 11: 980-985.
77. Lopez de Maturana R, Donnelly D, (2002). The glucagon-like peptide-1 receptor binding site for the N-terminus of GLP-1 requires polarity at Asp198 rather than negative charge. FEBS Lett 530: 244-248.
78. Lopez de Maturana R, Treece-Birch J, Abidi F, Findlay JB, Donnelly D, (2004). Met-204 and Tyr-205 are together important for binding GLP-1 receptor agonists but not their N-terminally truncated analogues. Protein Pept Lett 11: 15-22.
79. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, et al. (1998). RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393: 333-339.
80. Mann RJ, Al-Sabah S, de Maturana RL, Sinfield JK, Donnelly D, (2010). Functional coupling of Cys-226 and Cys-296 in the glucagon-like peptide-1 (GLP-1) receptor indicates a disulfide bond that is close to the activation pocket. Peptides 31: 2289-2293.
81. Mayo KE, Miller LJ, Bataille D, Dalle S, Goke B, Thorens B, et al. (2003). International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 55: 167-194.
82. Mierke DF, Mao L, Pellegrini M, Piserchio A, Plati J, Tsomaia N, (2007). Structural characterization of the parathyroid hormone receptor domains determinant for ligand binding. Biochem Soc Trans 35: 721-723.
83. Miller LJ, Dong M, (2013). The orthosteric agonist-binding pocket in the prototypic class B G-protein-coupled secretin receptor. Biochem Soc Trans 41: 154-158.
84. Miller LJ, Chen Q, Lam PC, Pinon DI, Sexton PM, Abagyan R, et al. (2011). Refinement of glucagon-like peptide 1 docking to its intact receptor using mid-region photolabile probes and molecular modeling. J Biol Chem 286: 15895-15907.
85. Monaghan P, Thomas BE, Woznica I, Wittelsberger A, Mierke DF, Rosenblatt M, (2008). Mapping peptide hormone-receptor interactions using a disulfide-trapping approach. Biochemistry 47: 5889-5895.
86. Moon MJ, Kim HY, Park S, Kim DK, Cho EB, Park CR, et al. (2012). Evolutionarily conserved residues at glucagon-like peptide-1 (GLP-1) receptor core confer ligand-induced receptor activation. J Biol Chem 287: 3873-3884.
87. Neumann JM, Couvineau A, Murail S, Lacapere JJ, Jamin N, Laburthe M, (2008). Class-B GPCR activation: is ligand helix-capping the key? Trends Biochem Sci 33: 314-319.
88. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, et al. (2000). Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289: 739-745.
89. Parthier C, Reedtz-Runge S, Rudolph R, Stubbs MT, (2009). Passing the baton in class B GPCRs: peptide hormone activation via helix induction? Trends Biochem Sci 34: 303-310.
90. Pellegrini M, Bisello A, Rosenblatt M, Chorev M, Mierke DF, (1998). Binding domain of human parathyroid hormone receptor: from conformation to function. Biochemistry 37: 12737-12743.
91. Perret J, Van Craenenbroeck M, Langer I, Vertongen P, Gregoire F, Robberecht P, et al. (2002). Mutational analysis of the glucagon receptor: similarities with the vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide (PACAP)/secretin receptors for recognition of the ligand's third residue. Biochem J 362: 389-394.
92. Pham V, Wade JD, Purdue BW, Sexton PM, (2004). Spatial proximity between a photolabile residue in position 19 of salmon calcitonin and the amino terminus of the human calcitonin receptor. J Biol Chem 279: 6720-6729.
93. Pham V, Dong M, Wade JD, Miller LJ, Morton CJ, Ng HL, et al. (2005). Insights into interactions between the alpha-helical region of the salmon calcitonin antagonists and the human calcitonin receptor using photoaffinity labeling. J Biol Chem 280: 28610-28622.
94. Piserchio A, Bisello A, Rosenblatt M, Chorev M, Mierke DF, (2000). Characterization of parathyroid hormone/receptor interactions: structure of the first extracellular loop. Biochemistry 39: 8153-8160.
95. Pozvek G, Hilton JM, Quiza M, Houssami S, Sexton PM, (1997). Structure/function relationships of calcitonin analogues as agonists, antagonists, or inverse agonists in a constitutively activated receptor cell system. Mol Pharmacol 51: 658-665.
96. Qi LJ, Leung AT, Xiong Y, Marx KA, Abou-Samra AB, (1997). Extracellular cysteines of the corticotropin-releasing factor receptor are critical for ligand interaction. Biochemistry 36: 12442-12448.
97. Rasmussen SG, Choi HJ, Fung JJ, Pardon E, Casarosa P, Chae PS, et al. (2011). Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature 469: 175-180.
98. Roberts DJ, Vertongen P, Waelbroeck M, (2011). Analysis of the glucagon receptor first extracellular loop by the substituted cysteine accessibility method. Peptides 32: 1593-1599.
99. Runge S, Gram C, Brauner-Osborne H, Madsen K, Knudsen LB, Wulff BS, (2003a). Three distinct epitopes on the extracellular face of the glucagon receptor determine specificity for the glucagon amino terminus. J Biol Chem 278: 28005-28010.
100. Runge S, Wulff BS, Madsen K, Brauner-Osborne H, Knudsen LB, (2003b). Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity. Br J Pharmacol 138: 787-794.
101. Sexton PM, Houssami S, Hilton JM, O'Keeffe LM, Center RJ, Gillespie MT, et al. (1993). Identification of brain isoforms of the rat calcitonin receptor. Mol Endocrinol 7: 815-821.
102. Solano RM, Langer I, Perret J, Vertongen P, Juarranz MG, Robberecht P, et al. (2001). Two basic residues of the h-VPAC1 receptor second transmembrane helix are essential for ligand binding and signal transduction. J Biol Chem 276: 1084-1088.
103. Stevens RC, Cherezov V, Katritch V, Abagyan R, Kuhn P, Rosen H, et al. (2013). The GPCR Network: a large-scale collaboration to determine human GPCR structure and function. Nat Rev Drug Discov 12: 25-34.
104. Sydow S, Flaccus A, Fischer A, Spiess J, (1999). The role of the fourth extracellular domain of the rat corticotropin-releasing factor receptor type 1 in ligand binding. Eur J Biochem 259: 55-62.
105. Tan YV, Couvineau A, Van Rampelbergh J, Laburthe M, (2003). Photoaffinity labeling demonstrates physical contact between vasoactive intestinal peptide and the N-terminal ectodomain of the human VPAC1 receptor. J Biol Chem 278: 36531-36536.
106. Tan YV, Couvineau A, Laburthe M, (2004). Diffuse pharmacophoric domains of vasoactive intestinal peptide (VIP) and further insights into the interaction of VIP with the N-terminal ectodomain of human VPAC1 receptor by photoaffinity labeling with [Bpa6]-VIP. J Biol Chem 279: 38889-38894.
107. Tan YV, Couvineau A, Murail S, Ceraudo E, Neumann JM, Lacapere JJ, et al. (2006). Peptide agonist docking in the N-terminal ectodomain of a class II G protein-coupled receptor, the VPAC1 receptor. Photoaffinity, NMR, and molecular modeling. J Biol Chem 281: 12792-12798.
108. Turner PR, Bambino T, Nissenson RA, (1996). A putative selectivity filter in the G-protein-coupled receptors for parathyroid hormone and secretion. J Biol Chem 271: 9205-9208.
109. Turner PR, Mefford S, Bambino T, Nissenson RA, (1998). Transmembrane residues together with the amino terminus limit the response of the parathyroid hormone (PTH) 2 receptor to PTH-related peptide. J Biol Chem 273: 3830-3837.
110. Unson CG, Wu CR, Jiang Y, Yoo B, Cheung C, Sakmar TP, et al. (2002). Roles of specific extracellular domains of the glucagon receptor in ligand binding and signaling. Biochemistry 41: 11795-11803.
111. Vertongen P, Solano RM, Perret J, Langer I, Robberecht P, Waelbroeck M, (2001). Mutational analysis of the human vasoactive intestinal peptide receptor subtype VPAC(2): role of basic residues in the second transmembrane helix. Br J Pharmacol 133: 1249-1254.
112. Vilardaga JP, di Paolo E, de Neef P, Waelbroeck M, Bollen A, Robberecht P, (1996). Lysine 173 residue within the first exoloop of rat secretin receptor is involved in carboxylate moiety recognition of Asp 3 in secretin. Biochem Biophys Res Commun 218: 842-846.
113. Vilardaga JP, Di Paolo E, Bialek C, De Neef P, Waelbroeck M, Bollen A, et al. (1997). Mutational analysis of extracellular cysteine residues of rat secretin receptor shows that disulfide bridges are essential for receptor function. Eur J Biochem 246: 173-180.
114. Vohra S, Taddese B, Conner AC, Poyner DR, Hay DL, Barwell J, et al. (2013). Similarity between class A and class B G-protein-coupled receptors exemplified through calcitonin gene-related peptide receptor modelling and mutagenesis studies. J R Soc Interface 10: 20120846.
115. Watkins HA, Au M, Hay DL, (2012). The structure of secretin family GPCR peptide ligands: implications for receptor pharmacology and drug development. Drug Discov Today 17: 1006-1014.
116. Wheatley M, Wootten D, Conner MT, Simms J, Kendrick R, Logan RT, et al. (2012). Lifting the lid on GPCRs: the role of extracellular loops. Br J Pharmacol 165: 1688-1703.
117. White JF, Noinaj N, Shibata Y, Love J, Kloss B, Xu F, et al. (2012). Structure of the agonist-bound neurotensin receptor. Nature 490: 508-513.
118. Willard FS, Sloop KW, (2012). Physiology and emerging biochemistry of the glucagon-like peptide-1 receptor. Exp Diabetes Res 2012: 470851.
119. Wittelsberger A, Corich M, Thomas BE, Lee BK, Barazza A, Czodrowski P, et al. (2006). The mid-region of parathyroid hormone (1-34) serves as a functional docking domain in receptor activation. Biochemistry 45: 2027-2034.
120. Wootten D, Simms J, Miller LJ, Christopoulos A, Sexton PM, (2013). Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations. Proc Natl Acad Sci U S A 110: 5211-5216.
121. Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katritch V, et al. (2010). Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330: 1066-1071.
122. Zang M, Dong M, Pinon DI, Ding XQ, Hadac EM, Li Z, et al. (2003). Spatial approximation between a photolabile residue in position 13 of secretin and the amino terminus of the secretin receptor. Mol Pharmacol 63: 993-1001.
123. Zhou AT, Bessalle R, Bisello A, Nakamoto C, Rosenblatt M, Suva LJ, et al. (1997). Direct mapping of an agonist-binding domain within the parathyroid hormone/parathyroid hormone-related protein receptor by photoaffinity crosslinking. Proc Natl Acad Sci U S A 94: 3644-3649.